Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03331250 |
Recruitment Status :
Active, not recruiting
First Posted : November 6, 2017
Last Update Posted : March 20, 2023
|
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | October 26, 2017 | ||||||
First Posted Date ICMJE | November 6, 2017 | ||||||
Last Update Posted Date | March 20, 2023 | ||||||
Actual Study Start Date ICMJE | January 18, 2018 | ||||||
Actual Primary Completion Date | July 21, 2022 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Objective Response Rate [ Time Frame: 2 years ] Partial response rate plus complete response rate by RECIST 1.1
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
|
||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | ||||||
Official Title ICMJE | A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | ||||||
Brief Summary | This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin |
||||||
Detailed Description | This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved Eribulin for your specific disease but it has been approved for other uses. In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE. Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules |
||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE | Drug: Eribulin
It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
Other Name: Halaven
|
||||||
Study Arms ICMJE | Experimental: Eribulin
Intervention: Drug: Eribulin
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Active, not recruiting | ||||||
Actual Enrollment ICMJE |
13 | ||||||
Original Estimated Enrollment ICMJE |
16 | ||||||
Estimated Study Completion Date ICMJE | May 31, 2025 | ||||||
Actual Primary Completion Date | July 21, 2022 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03331250 | ||||||
Other Study ID Numbers ICMJE | 17-355 | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Current Responsible Party | Gregory Cote, Massachusetts General Hospital | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor ICMJE | Massachusetts General Hospital | ||||||
Original Study Sponsor ICMJE | Same as current | ||||||
Collaborators ICMJE | Eisai Inc. | ||||||
Investigators ICMJE |
|
||||||
PRS Account | Massachusetts General Hospital | ||||||
Verification Date | March 2023 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |